Welcome to
On Feet Nation
Posted by Theresa on September 23, 2024 at 4:07am 0 Comments 0 Likes
Posted by se on September 23, 2024 at 4:07am 0 Comments 0 Likes
The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.
The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…
ContinueAdded by Esperanza Ruben on November 11, 2021 at 11:35am — No Comments
The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.
The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…
ContinueAdded by Esperanza Ruben on November 11, 2021 at 9:32am — No Comments
The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.
The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…
ContinueAdded by Esperanza Ruben on November 11, 2021 at 7:43am — No Comments
The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.
The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…
ContinueAdded by Esperanza Ruben on November 11, 2021 at 3:35am — No Comments
The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far Extra resources short of the company’s goals and Wall Street expectations.
The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a…
ContinueAdded by Esperanza Ruben on November 11, 2021 at 3:12am — No Comments
The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.
The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…
ContinueAdded by Esperanza Ruben on November 10, 2021 at 11:09pm — No Comments
The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.
The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…
ContinueAdded by Esperanza Ruben on November 10, 2021 at 9:30pm — No Comments
The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.
The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…
ContinueAdded by Esperanza Ruben on November 10, 2021 at 8:54pm — No Comments
The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.
The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…
ContinueAdded by Esperanza Ruben on November 10, 2021 at 8:16pm — No Comments
The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.
The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…
ContinueAdded by Esperanza Ruben on November 5, 2021 at 4:37pm — No Comments
The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.
The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…
ContinueAdded by Esperanza Ruben on November 5, 2021 at 12:46pm — No Comments
The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.
The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…
ContinueAdded by Esperanza Ruben on November 5, 2021 at 10:49am — No Comments
The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.
The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…
ContinueAdded by Esperanza Ruben on November 5, 2021 at 10:13am — No Comments
The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.
The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…
ContinueAdded by Esperanza Ruben on November 5, 2021 at 3:11am — No Comments
The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.
The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…
ContinueAdded by Esperanza Ruben on November 5, 2021 at 12:52am — No Comments
The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.
The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…
ContinueAdded by Esperanza Ruben on November 4, 2021 at 10:51pm — No Comments
The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.
The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…
ContinueAdded by Esperanza Ruben on November 4, 2021 at 10:09pm — No Comments
The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.
The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…
ContinueAdded by Esperanza Ruben on November 4, 2021 at 9:32pm — No Comments
The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.
The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…
ContinueAdded by Esperanza Ruben on October 28, 2021 at 1:50pm — No Comments
The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.
The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…
ContinueAdded by Esperanza Ruben on October 28, 2021 at 9:28am — No Comments
© 2024 Created by PH the vintage. Powered by